Balaxi Pharmaceuticals (NSE:BALAXI) Beneish M-Score: -2.24 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:BALAXI Balaxi Pharmaceuticals Ltd NSE:BALAXI
70 GF Score
Price ₹24.04
GF Value ₹69.51
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Balaxi Pharmaceuticals Beneish M-Score?

Balaxi Pharmaceuticals NSE:BALAXI -0.54% 70 Beneish M-Score is -2.24 as of Jul. 14, 2026. GuruFocus rates NSE:BALAXI with a GF Score™ of 70/100 and a GF Value™ of ₹69.51 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 911 Drug Manufacturers companies, Balaxi Pharmaceuticals ranks worse than 68.61% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.24 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Balaxi Pharmaceuticals's Beneish M-Score or its related term are showing as below:

NSE:BALAXI' s Beneish M-Score Range Over the Past 10 Years
Min: -2.51   Med: -1.28   Max: 3.38
Current: -2.24

During the past 12 years, the highest Beneish M-Score of Balaxi Pharmaceuticals was 3.38. The lowest was -2.51. And the median was -1.28.


Balaxi Pharmaceuticals Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Balaxi Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Balaxi Pharmaceuticals Beneish M-Score Chart

Balaxi Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.65 -1.28 -2.51 -0.84 -2.24

Balaxi Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.84 0.00 0.00 0.00 -2.24

NSE:BALAXI vs ZTS, UTHR: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Balaxi Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Balaxi Pharmaceuticals Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Balaxi Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Balaxi Pharmaceuticals's Beneish M-Score falls into.


NSE:BALAXI
70GF Score
Balaxi Pharmaceuticals Ltd NSE:BALAXI
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Balaxi Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Balaxi Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.298+0.528 * 0.982+0.404 * 1.0553+0.892 * 0.9235+0.115 * 1.1992
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.4314+4.679 * 0.017555-0.327 * 1.0252
=-2.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ₹1,365 Mil.
Revenue was ₹2,702 Mil.
Gross Profit was ₹1,193 Mil.
Total Current Assets was ₹2,514 Mil.
Total Assets was ₹3,370 Mil.
Property, Plant and Equipment(Net PPE) was ₹490 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹22 Mil.
Selling, General, & Admin. Expense(SGA) was ₹726 Mil.
Total Current Liabilities was ₹622 Mil.
Long-Term Debt & Capital Lease Obligation was ₹242 Mil.
Net Income was ₹14 Mil.
Gross Profit was ₹0 Mil.
Cash Flow from Operations was ₹-45 Mil.
Total Receivables was ₹1,139 Mil.
Revenue was ₹2,926 Mil.
Gross Profit was ₹1,269 Mil.
Total Current Assets was ₹2,428 Mil.
Total Assets was ₹3,103 Mil.
Property, Plant and Equipment(Net PPE) was ₹357 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹19 Mil.
Selling, General, & Admin. Expense(SGA) was ₹549 Mil.
Total Current Liabilities was ₹545 Mil.
Long-Term Debt & Capital Lease Obligation was ₹230 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1365.345 / 2701.735) / (1139.027 / 2925.612)
=0.505359 / 0.389329
=1.298

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1268.603 / 2925.612) / (1192.982 / 2701.735)
=0.43362 / 0.441561
=0.982

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2514.287 + 490.112) / 3370.295) / (1 - (2427.658 + 356.501) / 3103.424)
=0.108565 / 0.102875
=1.0553

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2701.735 / 2925.612
=0.9235

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(18.945 / (18.945 + 356.501)) / (21.529 / (21.529 + 490.112))
=0.05046 / 0.042078
=1.1992

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(725.788 / 2701.735) / (549.055 / 2925.612)
=0.268638 / 0.187672
=1.4314

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((242.124 + 621.576) / 3370.295) / ((230.457 + 545.321) / 3103.424)
=0.256268 / 0.249975
=1.0252

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(14.169 - 0 - -44.998) / 3370.295
=0.017555

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Balaxi Pharmaceuticals has a M-score of -2.24 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.24 mean?
Balaxi Pharmaceuticals (NSE:BALAXI) has a Beneish M-Score of -2.24 as of Jul. 14, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Balaxi Pharmaceuticals and its competitors. According to the industry distribution chart, Balaxi Pharmaceuticals ranks #625 out of 911 companies in the Drug Manufacturers industry, placing it in the top 68.6%.
Is Balaxi Pharmaceuticals' Beneish M-Score too high?
Balaxi Pharmaceuticals' current Beneish M-Score is -2.24. Based on the distribution chart, Balaxi Pharmaceuticals ranks #625 out of 911 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Balaxi Pharmaceuticals has a GF Score™ of 70/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Balaxi Pharmaceuticals' Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Balaxi Pharmaceuticals ranks #625 out of 911 companies for Beneish M-Score. This places Balaxi Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Balaxi Pharmaceuticals and its competitors. Balaxi Pharmaceuticals's current Beneish M-Score is -2.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Balaxi Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Balaxi Pharmaceuticals (NSE:BALAXI) is currently considered Possible Value Trap. The stock's GF Value™ is ₹69.51, compared to a current price of ₹24.04 — trading 65.4% below its estimated fair value. The current Beneish M-Score is -2.24. Balaxi Pharmaceuticals' overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Balaxi Pharmaceuticals (NSE:BALAXI), the current Beneish M-Score is -2.24 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Balaxi Pharmaceuticals (NSE:BALAXI) Overvalued in 2026?

Based on GuruFocus' analysis, Balaxi Pharmaceuticals stock appears to be undervalued. The current stock price of ₹24.04 is trading 65.4% below its estimated GF Value™ of ₹69.51. GuruFocus considers Balaxi Pharmaceuticals to be Possible Value Trap.

Key valuation signals for NSE:BALAXI:

  • Beneish M-Score: -2.24
  • GF Value™: ₹69.51 vs. price of ₹24.04 (65.4% below fair value)
  • GF Score™: 70/100 with 5 warning signs

No single metric tells the full story. See the NSE:BALAXI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Balaxi Pharmaceuticals Business Description

Address Phase-III, Road No: 81, Jubilee Hills, Plot No.409, H,No: 8-2-293, MAPS Towers, 3rd Floor, Hyderabad, TG, IND, 500 096
Balaxi Pharmaceuticals Ltd is an Indian branded IPR-based pharmaceutical company focusing on frontier markets, with a vast and growing portfolio of prescription and OTC drugs, across multiple therapeutic segments. The company operates in single segment Specialized Wholesale. Geographically it earns key revenue from Guatemala.
70GF Score

Get the complete analysis for NSE:BALAXI

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹24.04
Price
₹69.51
GF Value